mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice

Significance The RNA delivery field is mostly focused on lipid nanoparticles (LNPs). Although promising, LNPs have several limitations with respect to pharmacokinetics, biodistribution, and toxicity. The mechanism of RNA charge-altering releasable transporters (CART) delivery and release is unique. It proceeds dynamically with a controllable change in physical properties. Differing from all mRNA delivery systems, a key attribute of CARTs is a charge-altering degradation mechanism, which transforms the initial polycationic CART into neutral byproducts, thereby enabling endosomal escape, release, and subsequent translation of the polyanionic mRNA cargo. With this study, we introduce a potentially general approach to therapeutic vaccination enabled by a dynamic drug-delivery system (mRNA-CART) and demonstrate its utility in suppressing tumor formation and in eliminating established tumors. In vivo delivery of antigen-encoding mRNA is a promising approach to personalized cancer treatment. The therapeutic efficacy of mRNA vaccines is contingent on safe and efficient gene delivery, biological stability of the mRNA, and the immunological properties of the vaccine. Here we describe the development and evaluation of a versatile and highly efficient mRNA vaccine-delivery system that employs charge-altering releasable transporters (CARTs) to deliver antigen-coding mRNA to antigen-presenting cells (APCs). We demonstrate in human peripheral blood mononuclear cells that CART vaccines can activate a robust antigen-specific immune response against mRNA-encoded viral epitopes. In an established mouse model, we demonstrate that CARTs preferentially target professional APCs in secondary lymphoid organs upon i.v. injections and target local APCs upon s.c. injection. Finally, we show that CARTs coformulated with mRNA and a Toll-like receptor ligand simultaneously transfect and activate target cells to generate an immune response that can treat and cure mice with large, established tumors.

[1]  Daniel G. Anderson,et al.  Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs. , 2015, Nano letters.

[2]  Khalid A. Hajj,et al.  Tools for translation: non-viral materials for therapeutic mRNA delivery , 2017 .

[3]  Ash A. Alizadeh,et al.  Antigen Presentation Profiling Reveals Recognition of Lymphoma Immunoglobulin Neoantigens , 2017, Nature.

[4]  Shubiao Zhang,et al.  Toxicity of cationic lipids and cationic polymers in gene delivery. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[5]  D. Munn,et al.  Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype. , 2010, Blood.

[6]  C. Melief,et al.  Vaccines for established cancer: overcoming the challenges posed by immune evasion , 2016, Nature Reviews Cancer.

[7]  C. Heirman,et al.  The ReNAissanCe of mRNA-based cancer therapy , 2015, Expert review of vaccines.

[8]  R. Coffman,et al.  Vaccine adjuvants: putting innate immunity to work. , 2010, Immunity.

[9]  Murali Ramamoorth,et al.  Non viral vectors in gene therapy- an overview. , 2015, Journal of clinical and diagnostic research : JCDR.

[10]  R. Zinkernagel,et al.  In vivo antigen loading and activation of dendritic cells via a liposomal peptide vaccine mediates protective antiviral and anti-tumour immunity. , 2000, Vaccine.

[11]  J. Utikal,et al.  Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer , 2017, Nature.

[12]  M. Tanimoto,et al.  Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles. , 2004, Blood.

[13]  Daniel G. Anderson,et al.  Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose , 2016, Proceedings of the National Academy of Sciences.

[14]  Özlem Türeci,et al.  Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy , 2016, Nature.

[15]  Kevin Welsher,et al.  Deep-tissue anatomical imaging of mice using carbon nanotube fluorophores in the second near-infrared window , 2011, Proceedings of the National Academy of Sciences.

[16]  Özlem Türeci,et al.  mRNA-based therapeutics — developing a new class of drugs , 2014, Nature Reviews Drug Discovery.

[17]  H. Blau,et al.  Transient delivery of modified mRNA encoding TERT rapidly extends telomeres in human cells , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  D. Hoover,et al.  Comparison of Protective Efficacy of Subcutaneous versus Intranasal Immunization of Mice with a Brucella melitensis Lipopolysaccharide Subunit Vaccine , 2006, Infection and Immunity.

[19]  J. Pérez-Ortín,et al.  Eukaryotic mRNA decay: methodologies, pathways, and links to other stages of gene expression. , 2013, Journal of molecular biology.

[20]  M. Mirzakhani The Work , 2020, Citadel.

[21]  S. J. Payne,et al.  Multi-emissive difluoroboron dibenzoylmethane polylactide exhibiting intense fluorescence and oxygen-sensitive room-temperature phosphorescence. , 2007, Journal of the American Chemical Society.

[22]  Robert Langer,et al.  Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. , 2017, Nano letters.

[23]  I. Verma,et al.  Systemic delivery of factor IX messenger RNA for protein replacement therapy , 2017, Proceedings of the National Academy of Sciences.

[24]  Michael R. Green,et al.  Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. , 2013, The Journal of clinical investigation.

[25]  C. Contag,et al.  Functional DNA Delivery Enabled by Lipid-Modified Charge-Altering Releasable Transporters (CARTs). , 2018, Biomacromolecules.

[26]  Hao Zhu,et al.  Non-Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co-Delivery of Cas9 mRNA and sgRNA. , 2017, Angewandte Chemie.

[27]  Robert Langer,et al.  A combinatorial polymer library approach yields insight into nonviral gene delivery. , 2008, Accounts of chemical research.

[28]  K. Kataoka,et al.  Nanomaterial-Enabled Cancer Therapy. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  Y. Kaneda,et al.  RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization. , 1999, Human gene therapy.

[30]  R. Waymouth,et al.  Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters , 2018, Proceedings of the National Academy of Sciences.

[31]  T. Wu,et al.  Therapeutic HPV DNA vaccines , 2010, Immunologic research.

[32]  T. Friedmann,et al.  Gene Therapy for Human Genetic Disease? , 1972, Science.

[33]  J. R. Vargas,et al.  Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals , 2017, Proceedings of the National Academy of Sciences.

[34]  Gaurav Sahay,et al.  Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation. , 2012, Journal of the American Chemical Society.

[35]  G. Lenzen,et al.  Induction of virus‐specific cytotoxic T lymphocytes in vivo by liposome‐entrapped mRNA , 1993, European journal of immunology.